MLLCF
Molecular Partners AG

2
Loading...
Loading...
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274, and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
174

Frequently Asked Questions

What is Market Cap of Molecular Partners AG?
What is the 52-week high for Molecular Partners AG?
What is the 52-week low for Molecular Partners AG?
What is Molecular Partners AG stock price today?
What was Molecular Partners AG stock price yesterday?
What is the PE ratio of Molecular Partners AG?
What is the Price-to-Book ratio of Molecular Partners AG?
What is the 50-day moving average of Molecular Partners AG?
How many employess does Molecular Partners AG has?

Latest MLLCF News

View
No MLLCF news at the moment.

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.